Increased IV-TXA Dosage Reduces Blood Loss, Improves Pain and Clinical Outcomes in TKA Patients
Increased IV-TXA Dosage Reduces Blood Loss, Improves Pain and Clinical Outcomes in TKA Patients
Additional benefits of multiple-dose tranexamic acid to anti-fibrinolysis and anti-inflammation in total knee arthroplasty: a randomized controlled trial.
Arch Orthop Trauma Surg. 2020 Aug;140(8):1087-1095Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Two hundred and two patients with osteoarthrosis or rheumatoid arthritis undergoing a unilateral total knee arthroplasty were randomized to receive either one of the following interventions: 4 doses of Intravenous (IV) Tranexamic acid (TXA), 5 doses of IV-TXA, or 6 doses of IV-TXA or control (no TXA). The primary outcome of interest was hidden blood loss. Additional outcomes measured included the ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.